Probe composition, kit and method for detecting hemophilia related gene mutation type
By using targeted capture technology and third-generation sequencing in the same reaction system, combined with probe composition, the problem of difficulty in detecting multiple hemophilia gene mutations at the same time is solved in the prior art, and rapid and accurate detection is achieved, simplifying the Process and improve efficiency and accuracy.
Patent Information
- Application Number
- CN202411475698.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-22
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to detect multiple mutation types of multiple hemophilia-related genes in one system at the same time. Traditional methods are complex and not sensitive enough to provide complete genomic structural information.
Provide a probe composition and method to detect multiple hemophilia-related genes in the same reaction system by fragmenting the genomic DNA of the sample to be detected and adding a linker, using targeted capture technology combined with third-generation sequencing. mutation types include point mutations, deletions, duplications and other variants of F8, F9 and vWF genes.
It has achieved rapid and accurate detection of multiple hemophilia gene mutations, simplified the detection process, improved detection efficiency and accuracy, shortened the detection cycle, reduced costs, and was suitable for rapid clinical diagnosis.
Smart Images

Figure CN119061135A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of gene detection technology, and in particular to a probe composition, a kit and a method for detecting hemophilia-related gene mutation types. Background Art
[0002] Hemophilia is a group of inherited coagulation disorders, characterized by the lack or dysfunction of certain coagulation factors in the blood, which leads to prolonged coagulation time. Patients are prone to bleeding after minor injuries, and spontaneous bleeding may occur even without obvious trauma. Common hemophilias include hemophilia A (also known as coagulation factor VIII deficiency or hemophilia A), hemophilia B (also known as coagulation factor IX deficiency or hemophilia B), and hemophilia C (also known as coagulation factor XI deficiency). In addition, there are also congenital bleeding diseases caused by coagulation factor deficiency such as vascular hemophilia (vWD), coagulation factor II deficiency, and coagulation factor VII deficiency.
[0003] Hemophilia A (HA) is caused by a defect in the F8 gene. The F8 gene is located at Xq28, with a total length of approximately 186 kb, including 26 exons and 25 introns. The most common pathogenic variants of the F8 gene are intron 22 inversions, followed by intron 1 inversions. The remaining types of pathogenic variants span the entire mutation spectrum, including missense variants, small deletions or insertions, nonsense variants, splice site variants, large deletions and duplications, etc.
[0004] Hemophilia B (HB) is caused by a defect in the F9 gene. The F9 gene is located at Xq26.3-27.2, with a total length of about 32.7 kb, including 8 exons and 7 introns. Common pathogenic variants of the F9 gene are point mutations and small fragment insertions or deletions, which are distributed in exons, splicing regions and promoter regions, while the rest are large fragment deletions, which are partial exon deletions.
[0005] Von Willebrand disease (vWD) is caused by a defect in the vWF gene. The vWF gene is located at 12p13.3, with a total length of approximately 180 kb and 52 exons. VWD caused by a defect in the vWF gene is mainly divided into three types, each of which may contain different subtypes: ① Type 1, in which the amount of vWF is partially deficient, but the function is basically normal. ② Type 2, in which the function of vWF is abnormal, is further subdivided into four subtypes according to the different functions of vWF affected: Type 2A, in which high molecular weight vWF multimers are lacking, resulting in reduced platelet adhesion function; Type 2B, in which the affinity of vWF to platelet membrane glycoprotein GPⅠb is increased, resulting in a lack of high molecular weight vWF multimers; Type 2M, in which the distribution of vWF multimers is normal, but the adhesion activity to platelets is reduced; Type 2N, in which the affinity of vWF to FⅧ is reduced, resulting in a significant decrease in FⅧ activity. ③ Type 3: The amount of vWF is almost completely lacking. Each type of vWF gene defect may be caused by different genetic mutations, including missense mutations, nonsense mutations, insertion or deletion mutations, splice site mutations, promoter mutations, etc.
[0006] In summary, the pathogenic genes and mutation sites of hemophilia are diverse, including point mutations, small insertions or deletions, large deletions, intron inversions, etc., and it is difficult to detect multiple mutation types simultaneously in one system. Traditional molecular analysis of hemophilia usually requires a combination of multiple detection methods, such as long-range polymerase chain reaction (LR-PCR) or inverse PCR for detecting inversions, Sanger sequencing or next-generation sequencing (NGS) for detecting single nucleotide variants (SNVs) and insertions and deletions, and multiplex ligation-dependent probe amplification (MLPA) for detecting large deletions or duplications. Although these methods have their own advantages, they also have limitations, such as not being sensitive enough to detect large-fragment mutations or being unable to provide complete genomic structure information. Therefore, establishing a rapid and accurate detection technology for pathogenic gene mutations that can simultaneously detect multiple congenital bleeding diseases such as hemophilia is of great significance for the early identification and diagnosis and treatment of hemophilia. Summary of the invention
[0007] Based on this, one or more embodiments of the present application provide a probe composition, a kit and a method that can detect multiple mutation types of multiple hemophilia-related genes in the same reaction system.
[0008] The technical solution of this application includes the following contents:
[0009] A probe composition for detecting mutation types of hemophilia-related genes, wherein the hemophilia-related genes include F8, F9 and vWF; the start and end sites of the probe composition are as follows:
[0010]
[0011]
[0012]
[0013] A kit for detecting the type of hemophilia-related gene mutations, comprising the probe composition described above.
[0014] A method for detecting the type of hemophilia-related gene mutation, comprising:
[0015] The genomic DNA of the sample to be tested is fragmented and adapter-added to obtain DNA fragments with adapters added to the ends;
[0016] The DNA fragment with a linker added to the end is subjected to hybridization capture treatment using the probe composition described above to obtain a hybridization capture product;
[0017] amplifying the hybridization capture product to obtain an amplified product;
[0018] Using the amplified products to construct a third-generation library, sequencing, and obtaining sequence reads;
[0019] The sequence reads are compared with a reference genome to obtain mutation results of hemophilia-related genes in the sample to be tested.
[0020] Furthermore, the step of subjecting the DNA fragment with a linker added to the end to hybrid capture treatment with the probe composition described above to obtain a hybrid capture product comprises:
[0021] The DNA fragment with a connector added to the end is amplified, and then subjected to fragment screening to obtain a first amplification product, wherein the proportion of DNA fragments with a length of 5000 bp to 15000 bp in the first amplification product is ≥ 80%;
[0022] The selected fragments were subjected to hybridization capture treatment using the probe composition described above.
[0023] Furthermore, the step of screening the DNA fragments with adapters added to the ends after amplification includes:
[0024] The product after the first amplification treatment is co-incubated with DNA screening magnetic beads, and the volume ratio of the product after the first amplification treatment to the 35% DNA screening magnetic beads is 1: (3.1-3.3).
[0025] Furthermore, the step of comparing the sequence reads with the reference genome to obtain the mutation results of the hemophilia-related genes in the sample to be tested includes:
[0026] Compare the sequence reads with a reference genome, align a portion of the sequence reads to a conventional gene region to obtain a first comparison result, perform a first variation analysis based on the first comparison result, output the first analysis result, perform haplotype typing on the unconventional gene, obtain a differential base sequence between the unconventional gene and a highly homologous sequence existing therein, compare the differential base sequence with the remaining portion of the sequence reads to obtain a second comparison result, perform a second variation analysis based on the second comparison result, and output a second analysis result;
[0027] Summarizing the first analysis result and the second analysis result, and outputting a gene mutation analysis result;
[0028] Among them, the conventional gene refers to a gene without a highly homologous sequence, the unconventional gene refers to a gene with a highly homologous sequence, and the gene with a highly homologous sequence means that the gene has a homologous sequence with a similar sequence structure within the genome, and the similarity between the gene sequence and the homologous sequence is ≥90%;
[0029] The first analysis result and the second analysis result each independently include at least one of the following gene mutation results: single nucleotide polymorphism, small-scale insertion and deletion, structural variation and complex genome rearrangement.
[0030] A device for detecting hemophilia-related gene mutation types, comprising:
[0031] Genomic DNA processing module: used to fragment and add adapters to the genomic DNA of the sample to be tested to obtain DNA fragments with adapters added to the ends;
[0032] Target region capture module: used to perform hybridization capture treatment on the DNA fragment with a connector added to the end using the probe composition described above to obtain a hybridization capture product; and to perform amplification treatment on the hybridization capture product to obtain an amplified product;
[0033] Sequencing module: construct a third-generation library with the amplified product, sequence it, and obtain sequence readings; compare the sequence readings with the reference genome to obtain the mutation results of the hemophilia-related genes in the sample to be tested.
[0034] A computer device comprises a memory and a processor, wherein the memory stores a computer program, and the processor implements the steps of the method described above when executing the computer program.
[0035] A computer-readable storage medium stores a computer program, which implements the steps of the method described above when executed by a processor.
[0036] A computer program product comprises a computer program, which implements the steps of the method described above when executed by a processor.
[0037] The technical solution of this application includes at least the following beneficial effects:
[0038] (1) The present application provides a probe composition, a kit and a method that can detect multiple mutation types of multiple hemophilia-related genes in the same reaction system. The method is suitable for people with normal phenotypes or those with phenotypes, and can perform carrier screening and diagnosis of multiple mutation types of multiple genes of hemophilia at one time, and can simultaneously detect point mutations, deletions and duplications, copy number variations and structural variations as well as gender identification in the same reaction system, and can realize molecular typing for test samples with clinical indications.
[0039] (2) The current molecular analysis process for hemophilia is complex and requires the combination of multiple technologies. This application greatly simplifies the detection process by combining third-generation sequencing with targeted capture technology, achieving "one-step" detection and improving detection efficiency.
[0040] (3) Compared with multi-method combined detection technology, the detection method of the present application covers all variant types at one time, greatly shortens the detection cycle, and reduces the detection cost, and is more suitable for clinical applications that require rapid diagnosis.
[0041] (4) The detection method of the present application improves the accuracy of variant identification, can simultaneously detect multiple pathogenic genes of multiple diseases, can cover all target regions of the target gene, increase the sequencing depth of the target region, and improve the accuracy of variant identification. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0043] Figure 1 This is a comparison chart of the coverage of the F9 region before and after the optimization of the probe composition of Example 1 of the present application;
[0044] Figure 2 This is a fragment distribution comparison diagram of Example 2 of the present application after the first amplification (before hybridization capture) and without screening, and a fragment distribution comparison diagram of the library after capture obtained respectively;
[0045] Figure 3 is the IGV spectrum of sample 1 of Example 3 of the present application;
[0046] Figure 4 is the IGV spectrum of sample 2 of Example 3 of the present application;
[0047] Figure 5 This is the IGV spectrum of sample 3 of Example 3 of the present application. DETAILED DESCRIPTION
[0048] The present application will be further described below in conjunction with the embodiments and examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. In addition, it should be understood that after reading the content taught in the present application, those skilled in the art may make various changes or modifications to the present application, and these equivalent forms also fall within the protection scope of the claims attached to the present application.
[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0050] the term
[0051] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0052] The term "and / or" used in this article includes any one of two or more related listed items, and also includes any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").
[0053] Herein, "preferred", "preferable", "better", etc. are only used to describe implementation methods or examples with better effects. It should be understood that they do not constitute limitations on the scope of protection of this application.
[0054] In the present application, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.
[0055] In this application, "first", "second", "third", "fourth", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.
[0056] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0057] In the present application, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.
[0058] In the present application, weight may be μg, mg, g, kg, or other mass units known in the biological field.
[0059] An embodiment of the present application provides a probe composition for detecting mutation types of hemophilia-related genes, wherein the hemophilia-related genes include F8, F9 and vWF;
[0060] The start and end sites of the probe sequences included in the probe composition are shown in Table 1 above.
[0061] An embodiment of the present application provides a kit for detecting hemophilia-related gene mutation types, comprising the above probe composition.
[0062] An embodiment of the present application provides a method for detecting a hemophilia-related gene mutation type, comprising:
[0063] The genomic DNA of the sample to be tested is fragmented and adapter-added to obtain DNA fragments with adapters added to the ends;
[0064] The DNA fragment with a linker added to the end is subjected to hybridization capture treatment using the above probe composition to obtain a hybridization capture product;
[0065] amplifying the hybridization capture product to obtain an amplified product;
[0066] The second amplification product was used to construct a third-generation library, which was sequenced to obtain sequence reads;
[0067] The sequence reads are compared with the reference genome to obtain the mutation results of hemophilia-related genes in the sample to be tested.
[0068] In one embodiment, the step of performing hybridization capture treatment on a DNA fragment with a linker added to the end with the probe composition described above to obtain a hybridization capture product comprises:
[0069] The DNA fragments with adapters added to the ends are amplified, and then subjected to fragment screening to obtain a first amplification product, wherein the proportion of DNA fragments with a length of 5000 bp to 15000 bp in the first amplification product is ≥ 80%;
[0070] The selected fragments were subjected to hybridization capture treatment using the above probe composition.
[0071] After the DNA fragments with adapters added to the ends are amplified, the fragment screening process is performed to obtain the first amplified product. This is mainly because the amplification efficiency of the amplification enzyme may be affected by the length of the DNA template. Short fragments may be easier to amplify due to their lower amplification difficulty, resulting in a higher copy number than long fragment templates. The high proportion of small fragments at the same sequencing depth will affect the assembly effect. Therefore, it is necessary to remove library molecules smaller than 5kb in the pre-capture library as much as possible. Optionally, screening magnetic beads can be used to screen out small fragments at a specific ratio.
[0072] In one embodiment, the step of screening the DNA fragments with adapters added to the ends after amplification includes:
[0073] Co-incubating the product after the first amplification treatment with DNA screening magnetic beads;
[0074] The volume ratio of the product after the first amplification treatment to the DNA screening magnetic beads is 1:(3.1-3.3).
[0075] Optionally, the product after the first amplification treatment and the DNA screening magnetic beads are co-incubated at a second temperature for a second time.
[0076] Optionally, the second temperature is 20°C to 40°C, and the second time is 15min to 25min.
[0077] Optionally, the DNA screening magnetic beads are selected from AMPure PB magnetic beads.
[0078] Optionally, the DNA screening magnetic beads are prepared into a 35% solution and incubated with the product after the first amplification treatment, and the volume ratio of the product after the first amplification treatment to the solution is 1:(3.1-3.3), for example 1:3.1, 1:3.2, 1:3.3, etc.
[0079] In one embodiment, the step of comparing the sequence reads with the reference genome to obtain the mutation results of the hemophilia-related gene in the sample to be tested includes:
[0080] Compare the sequence reads with the reference genome, align a portion of the sequence reads to the conventional gene region to obtain a first comparison result, perform a first variation analysis based on the first comparison result, output the first analysis result, perform haplotype typing on the unconventional gene, obtain a differential base sequence between the unconventional gene and its highly homologous sequence, compare the differential base sequence with the remaining portion of the sequence reads to obtain a second comparison result, perform a second variation analysis based on the second comparison result, and output the second analysis result;
[0081] Summarizing the first analysis result and the second analysis result, and outputting the gene mutation analysis result;
[0082] Among them, conventional genes refer to genes without highly homologous sequences, and unconventional genes refer to genes with highly homologous sequences. Genes with highly homologous sequences refer to genes with homologous sequences with similar sequence structures within the genome, and the similarity between the gene sequence and the homologous sequence is ≥90%;
[0083] The first analysis result and the second analysis result each independently include at least one of the following gene mutation results: single nucleotide polymorphism, small-scale insertion and deletion, structural variation and complex genome rearrangement.
[0084] An embodiment of the present application provides a device for detecting hemophilia-related gene mutation types, comprising:
[0085] Genomic DNA processing module: used to fragment and add adapters to the genomic DNA of the sample to be tested to obtain DNA fragments with adapters added to the ends;
[0086] Target region capture module: used to perform hybrid capture processing on the DNA fragments with connectors added to the ends to obtain hybrid capture products; perform amplification processing on the hybrid capture products to obtain amplified products;
[0087] Sequencing module: used to construct a third-generation library with amplification products, sequence, and obtain sequence reads; compare the sequence reads with the reference genome to obtain the mutation results of hemophilia-related genes in the sample to be tested.
[0088] An embodiment of the present application provides a computer device, including a memory and a processor, wherein the memory stores a computer program, and the processor implements the steps of the above method when executing the computer program.
[0089] An embodiment of the present application provides a computer-readable storage medium on which a computer program is stored. When the computer program is executed by a processor, the steps of the above method are implemented.
[0090] An embodiment of the present application provides a computer program product, including a computer program, which implements the steps of the above method when executed by a processor.
[0091] The following are some specific embodiments.
[0092] For experimental parameters not specified in the following specific embodiments, reference is made to the instructions given in the present application document, and reference may also be made to experimental manuals in the art or other experimental methods known in the art, or to experimental conditions recommended by manufacturers.
[0093] The raw materials and reagents involved in the following specific examples can be obtained from commercial sources, or can be prepared by those skilled in the art according to known methods.
[0094] Example 1
[0095] This embodiment optimizes the probe set, as follows:
[0096] The first version of the targeted capture RNA probe was designed for the full-length regions of F8, F9, vWF and SRY. After testing the first version of the probe, it was found that the coverage of the F9 terminal region was low. Based on this test result, a probe was added to the last exon region of the F9 gene (chrX:138643683-138645618). The optimized probe composition is shown in Table 1.
[0097] Table 1 Optimized probe information.
[0098]
[0099]
[0100]
[0101] The coverage of F9 region before and after probe optimization can also be seen in Figure 1 , Figure 1 It can be seen intuitively that the optimized probe has more comprehensive coverage, improving the coverage of the last exon region of the F9 gene (chrX:138643683-138645618), ensuring full coverage of the target gene.
[0102] Example 2
[0103] Since the PCR amplification enzyme has a preference for amplifying short fragments first, the content of short fragments increases after the first amplification. In order to smoothly carry out the next step of hybridization capture, the short fragments after the first amplification can be removed first.
[0104] In this example, the conditions for fragment screening were optimized as follows: 2500 ng of the first amplification product was supplemented with water to 50 μL, 3.1× 35% (v / v) AMPure PB magnetic beads were added thereto, and the supernatant was removed after incubation at room temperature for 20 min, so that fragments below 5 kb could be removed.
[0105] The statistics of the fragments obtained after the first amplification (before hybridization capture) and without screening are shown in Tables 2 and Figure 2 According to Table 2, after fragment screening, the peak value of fragment distribution obtained by hybridization capture and the proportion of 5000-15000bp were significantly improved.
[0106] Table 2 Comparison of fragment distribution before and after screening
[0107]
[0108] Example 3
[0109] This example is the detection process and results of gene mutations in three hemophilia positive samples using the method of the present application, as follows:
[0110] 1. Extract sample DNA: The above three samples were provided by Dushu Lake Hospital. Genomic DNA was extracted from 200 μL peripheral blood using a nucleic acid extraction kit (this process is compatible with DNA extracted by magnetic beads, column and automated methods).
[0111] 2. Process sample DNA (fragmentation, linker, purification and amplification)
[0112] Take 1μg gDNA, add 10μL Tagment Buffer, 3μL Tagment Enzyme, add water to 50μL, react at 55℃ for 10 minutes, then add 10μL stop buffer, react at 55℃ for 5 minutes, and purify with magnetic beads.
[0113] 22 μL of the purified product was added with 3 μL of primers with specific tags and 25 μL of 2×KeyPo SE MasterMix (Dye Plus), and the reaction was carried out according to the procedure in Table 3 and then purified with 0.8X purification magnetic beads.
[0114] Table 3
[0115]
[0116]
[0117] Use 3.1×35% AMPure PB magnetic beads to screen the pre-capture library, incubate at room temperature for 20 minutes, remove the supernatant and wash with 80% alcohol, and small fragments below 5kb can be removed after elution.
[0118] 3. Hybridization captures the target region of sample DNA
[0119] The fragments screened in 2.2 were hybridized with the probe combination, including the following steps: 750-2000 ng of the screened product was concentrated using 1× purification magnetic beads, and then 30 μL of hybridization solution was used for elution. The components of the hybridization solution were shown in Table 4.
[0120] Table 4
[0121] Components Volume (μL) Hybridization buffer 13 Blocking Buffer 1 5 Universal Blocking Buffer (Illumina Nextera) 2 Blocking Buffer 3 5 Nuclease-free water 3 Probe 2 Total volume 30
[0122] Hybridization temperature: hot cover 85℃, incubate at 80℃ for 5min, and maintain at 50℃ for 12-18 hours.
[0123] After hybridization, it was bound to streptavidin magnetic beads and washed 4 times with heat to remove non-specific fragments; according to TargetSeq Just follow the instruction manual of Hyb&Wash Kit v2.0.
[0124] 23 μL of the hybridization capture product was added with 2 μL Post PCR Primer and 25 μL 2×KeyPo SE MasterMix (Dye Plus), and the reaction was carried out according to the procedure in Table 5, and then purified with 0.8× purification magnetic beads.
[0125] Table 5
[0126]
[0127] 4. Construction of third-generation library and sequencing analysis
[0128] The purified fragments were used to construct the third-generation library: Preparing multiplexed amplicon libraries using Prep kit 3.0 was used to construct a third-generation library (this example uses PacBio library construction as an example, and this process is compatible with the ONT platform).
[0129] The third-generation library is sequenced on a machine to obtain sequence reads, which are then compared with the reference genome to obtain the variation results of the sample.
[0130] 5. Results of sequencing analysis
[0131] The variation information obtained based on sequencing analysis is shown in Table 6.
[0132] Table 6
[0133]
[0134] Sample 1: ZYC, the known mutation information is the inversion of intron 22 of the F8 gene. The results of the detection and analysis using the method of this application are shown in Figure 3 ,Depend on Figure 3 It can be seen intuitively that fusion inversion occurred at Int22h1-int22h3 within the F8 gene.
[0135] Sample 2: LCM, the known mutation information is the inversion of intron 22 of the F8 gene. The results of the detection and analysis using the method of this application are shown in Figure 4 ,Depend on Figure 4 It can be seen intuitively that fusion inversion occurred at Int22h1-int22h3 within the F8 gene.
[0136] Sample 3: A1, the known mutation information is the inversion of intron 22 of the F8 gene. The results of the detection and analysis using the method of this application are shown in Figure 5 ,Depend on Figure 5 It can be seen intuitively that fusion inversion occurred at Int22h1-int22h3 within the F8 gene.
[0137] According to the above test results, the probe composition of the present application can comprehensively and accurately detect the mutation types of hemophilia-related genes, and can detect variation information including point mutations, deletions and duplications, as well as relatively more complex copy number variation and structural variation information.
[0138] Traditional detection methods need to combine multiple detection methods to achieve comprehensive detection of mutation types. The present application realizes comprehensive detection of multiple mutation types of multiple genes of hemophilia in one reaction system at one time, simplifies the detection process, improves detection efficiency, greatly shortens the detection cycle, and meets the clinical need for rapid diagnosis.
[0139] The detection method of the present application has high accuracy in variant identification, and combines the advantages of third-generation long-read sequencing with probe targeted capture technology. It can not only cover all regions of the target gene, increase the sequencing depth of the target region, and improve the accuracy of variant identification, but also avoid the high price of third-generation whole genome sequencing.
[0140] All documents mentioned in this application are cited as references in this application, just as each document is cited as reference separately. Unless they conflict with the application purpose and / or technical solution of this application, the cited documents involved in this application are cited with all contents and all purposes. When the cited documents are involved in this application, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the cited documents are involved in this application, the examples and preferred methods of the cited relevant technical features can also be incorporated into this application as references, but are limited to the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, the present application shall prevail or be modified adaptively according to the description of this application.
[0141] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0142] The above-described embodiments only express several implementation methods of the present application, but they cannot be understood as limiting the scope of the patent application. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present application, several variations and improvements can also be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, those skilled in the art can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by those skilled in the art on the basis of the technical solutions provided in the present application through logical analysis, reasoning or limited experiments are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the attached claims, and the description can be used to interpret the content of the claims.
Claims
1. A probe composition for detecting hemophilia-related gene mutation types, characterized in that: The hemophilia-related genes include F8, F9 and vWF; the start and end sites of the probe composition are as follows:
2. A kit for detecting hemophilia-related gene mutation types, characterized in that: The probe composition comprises the probe composition according to claim 1.
3. A method for detecting the type of hemophilia-related gene mutation, characterized in that: include: The genomic DNA of the sample to be tested is fragmented and adapter-added to obtain DNA fragments with adapters added to the ends; The DNA fragment with a linker added to the end is subjected to hybridization capture treatment using the probe composition of claim 1 to obtain a hybridization capture product; amplifying the hybridization capture product to obtain an amplified product; Using the amplified products to construct a third-generation library, sequencing, and obtaining sequence reads; The sequence reads are compared with a reference genome to obtain mutation results of hemophilia-related genes in the sample to be tested.
4. The method according to claim 3, characterized in that The step of subjecting the DNA fragment with a linker added to the end to hybrid capture treatment with the probe composition of claim 1 to obtain a hybrid capture product comprises: The DNA fragment with a connector added to the end is amplified, and then subjected to fragment screening to obtain a first amplification product, wherein the proportion of DNA fragments with a length of 5000 bp to 15000 bp in the first amplification product is ≥ 80%; The screened fragments are subjected to hybridization capture treatment using the probe composition of claim 1.
5. The method according to claim 4, characterized in that The steps of screening the DNA fragments with adapters added to the ends after amplification include: The product after the first amplification treatment is co-incubated with the DNA screening magnetic beads, and the volume ratio of the product after the first amplification treatment to the 35% DNA screening magnetic beads is 1:(3.1-3.3).
6. The method according to claim 3, characterized in that The step of comparing the sequence reads with a reference genome to obtain mutation results of hemophilia-related genes in the sample to be tested comprises: Compare the sequence reads with a reference genome, align a portion of the sequence reads to a conventional gene region to obtain a first comparison result, perform a first variation analysis based on the first comparison result, output the first analysis result, perform haplotype typing on the unconventional gene, obtain a differential base sequence between the unconventional gene and a highly homologous sequence existing therein, compare the differential base sequence with the remaining portion of the sequence reads to obtain a second comparison result, perform a second variation analysis based on the second comparison result, and output a second analysis result; Summarizing the first analysis result and the second analysis result, and outputting a gene mutation analysis result; Among them, the conventional gene refers to a gene without a highly homologous sequence, the unconventional gene refers to a gene with a highly homologous sequence, and the gene with a highly homologous sequence means that the gene has a homologous sequence with a similar sequence structure within the genome, and the similarity between the gene sequence and the homologous sequence is ≥90%; The first analysis result and the second analysis result each independently include at least one of the following gene mutation results: single nucleotide polymorphism, small-scale insertion and deletion, structural variation and complex genome rearrangement.
7. A device for detecting hemophilia-related gene mutation types, characterized in that: include: Genomic DNA processing module: used to fragment and add adapters to the genomic DNA of the sample to be tested to obtain DNA fragments with adapters added to the ends; Target region capture module: used for performing hybridization capture treatment on the DNA fragment with a connector added to the end with the probe composition of claim 1 to obtain a hybridization capture product; performing amplification treatment on the hybridization capture product to obtain an amplification product; Sequencing module: used to construct a third-generation library with the amplified product, sequence it, and obtain sequence readings; compare the sequence readings with the reference genome to obtain the mutation results of the hemophilia-related genes in the sample to be tested.
8. A computer device comprising a memory and a processor, wherein the memory stores a computer program, wherein: When the processor executes the computer program, the steps of the method according to any one of claims 3 to 6 are implemented.
9. A computer-readable storage medium having a computer program stored thereon, characterized in that: When the computer program is executed by a processor, the steps of the method according to any one of claims 3 to 6 are implemented.
10. A computer program product, comprising a computer program, characterized in that When the computer program is executed by a processor, the steps of the method according to any one of claims 3 to 6 are implemented.
